Stock analysts at Leerink Swann boosted their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $445.00 to $527.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Leerink Swann’s target price ... · 4/24/2015
Regeneron Pharmaceuticals ((REGN - Analyst Report)) is a biopharmaceutical company ... The successful development of the candidates would boost the stock significantly. The company has recorded positive earnings surprises in two of the trailing four ...
ZACKS · 5/7/2015
Big-cap biotech Regeneron Pharmaceuticals (NASDAQ:REGN) beat Wall Street's Q1 estimates and raised its guidance Thursday, sending the stock up more than 2% in early trading. Regeneron's earnings rose 27% over the year-earlier quarter to $2.88 a …
Investors Business Daily · ByAmy Reeves · 5/7/2015
More from Bing News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at 514.22 on Thursday. Regeneron Pharmaceuticals Inc has a 52-week low of $269.50 and a 52-week high of $519.46. The stock’s 50-day moving average is $483. and its 200-day moving average …
Mideast Times · 7/5/2015
This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward. MannKind (NASDAQ:MNKD) ranks first with a loss of 6.55%; Regeneron Pharmaceuticals (NASDAQ …
Financial News Network Online · ByPeter Chu · 6/12/2015
... Cramer claimed to have first recommended Regeneron when the stock was trading at $5 a share. In late-morning trading Wednesday, REGN was hovering around the $330 level. "This is a wonder of this market," Cramer said of REGN. "I still like it very …
CNBC · ByDrew Sandholm · 7/30/2014
REGN closed Tuesday's trading at $526.09, unchanged from the previous day's close. In after-hours, the stock was down 2.70% to $511.90. SAGE Therapeutics Inc.'s (SAGE) epilepsy candidate SAGE-547 has demonstrated a statistically significant …
Realtime Business News · 6/10/2015
The FMHR traders take their positions on four stocks making news today, including Target officially raising the dividend, and increasing its buyback. CNBC 3:48
MSN · 6/10/2015
Although committee members raised questions regarding the long-term safety profile of Amgen's (NASDAQ: AMGN) Repatha and Regeneron's (NASDAQ: REGN) Praluent ... too late to the party -- click here for one stock to own when the Web goes dark.
Investopedia · 6/15/2015
Within the biotech sector, there are, of course, stronger and weaker stocks. One of my favorites in the group is Regeneron Pharmaceuticals (NASDAQ: REGN), which makes products to treat cancer, inflammation and other conditions. No doubt, this stock
NASDAQ · 4/3/2015


Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in …
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, it branched out into the study of both cytokine and tyrosine kinase receptors.
Data from: Wikipedia · Freebase